The identification of autoantibodies like anti-TIF1-γ now serves as a highly specific marker for cancer-associated DM, mandating immediate and targeted oncological screening [8-10]. This paradigm shift, from generalized suspicion to precise, antibody-guided risk stratification, highlights the urgent need for clinicians to integrate these novelties into their diagnostic workflow to facilitate the early detection of hidden tumors [3]. This evidence concerns the gene TRIM33 and dermatomyositis.